anmelden
OMX Copenhagen 20
1.614,22
PKT
-3,08
PKT
-0,19
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 04.12.20 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG | |
| 01.12.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 23.11.20 | A.P. Moeller - Maersk A-S (B) kaufen | Credit Suisse Group | |
| 23.11.20 | A.P. Moeller - Maersk A-S (B) kaufen | Goldman Sachs Group Inc. | |
| 20.11.20 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 19.11.20 | A.P. Moeller - Maersk A-S (B) Sell | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 19.11.20 | A.P. Moeller - Maersk A-S (B) Underweight | Barclays Capital | |
| 19.11.20 | A.P. Moeller - Maersk A-S (B) buy | Kepler Cheuvreux | |
| 18.11.20 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 16.11.20 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 13.11.20 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 12.11.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 09.11.20 | Novo Nordisk Neutral | UBS AG | |
| 09.11.20 | Novo Nordisk Underweight | Morgan Stanley | |
| 06.11.20 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 06.11.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.11.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.11.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.11.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 02.11.20 | Novo Nordisk Neutral | UBS AG | |
| 02.11.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 31.10.20 | Novo Nordisk kaufen | Bernstein Research | |
| 30.10.20 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 30.10.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 30.10.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 30.10.20 | Novo Nordisk Neutral | UBS AG | |
| 30.10.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 27.10.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 16.10.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 15.10.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 15.10.20 | A.P. Moeller - Maersk A-S (B) buy | Kepler Cheuvreux | |
| 14.10.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 14.10.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 13.10.20 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 13.10.20 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 12.10.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 09.10.20 | Novo Nordisk Neutral | UBS AG | |
| 09.10.20 | Novo Nordisk Verkaufen | DZ BANK | |
| 09.10.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 09.10.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. |
